Financial Performance - For the fiscal year ending March 31, 2023, the company's revenue increased by approximately 6.6% to about HKD 76.7 million from approximately HKD 72 million for the previous year[10]. - Gross profit rose by approximately HKD 3.2 million or 8.7% to about HKD 39.5 million, with the gross profit margin increasing from approximately 50.5% to 51.5%[11]. - The company's net profit increased from approximately HKD 4 million to about HKD 7.6 million, primarily due to increased revenue and a one-time government subsidy for employment retention[15]. - Administrative and other operating expenses rose by approximately HKD 1.3 million or 4.2% to about HKD 30.5 million, mainly due to increased rent and management fees[12]. - The tax expense for the fiscal year was approximately HKD 1.8 million, up from HKD 1.4 million in the previous year[13]. - The interim dividend declared for the year ending March 31, 2023, is HKD 0.4 per share, an increase from HKD 0.3 per share in 2022[16]. - The company reported a strong performance for the fiscal year ending March 31, 2023, with a total revenue increase of 15% compared to the previous year[56]. - Total revenue for the reporting period was approximately HKD 76.7 million, an increase from HKD 72 million in the previous fiscal year, representing a growth of about 9.72%[159]. Market Outlook and Strategy - The company is optimistic about the healthcare sector's future, driven by an aging population and increased health awareness in Hong Kong[6]. - A joint venture has been established to promote the development of autonomous mobile robotic solutions in the healthcare industry[9]. - The company plans to further diversify its product offerings and enhance customer service to improve its one-stop medical equipment solution[9]. - The economic recovery following the lifting of COVID-19 restrictions has positively impacted revenue from medical equipment and supplies[10]. - The company is actively seeking suitable investment opportunities to achieve business diversification and enhance shareholder returns[6]. - New product launches are anticipated to contribute significantly to revenue, with an estimated impact of DD million in the upcoming quarter[45]. - Market expansion efforts are underway, targeting new regions with a projected market size of $FF billion[45]. - The company is exploring potential acquisitions to enhance its market position, with a focus on companies valued at GG million[45]. - Strategic partnerships are being formed to leverage synergies, aiming for a combined revenue increase of HH%[45]. Corporate Governance - The board of directors has maintained a high level of corporate governance, adhering to all relevant guidelines and principles[57]. - The company has complied with GEM listing rules by appointing at least 3 independent non-executive directors, with one possessing relevant financial expertise[69]. - The chairman and CEO roles are held by the same individual, Ms. Huang, who is responsible for overall strategy and major decisions[71]. - The audit committee held 5 meetings during the fiscal year ending March 31, 2023, reviewing financial reports and risk management procedures[78]. - The audit committee is composed of 2 independent non-executive directors and 1 non-executive director[75]. - The company has established a remuneration committee in compliance with GEM listing rules since March 1, 2018[80]. - The board regularly reviews the performance of management and requires board approval for significant transactions[68]. - The company ensures that all directors can seek independent professional advice at the company's expense[73]. - The board is committed to maintaining high standards of corporate governance and compliance with relevant regulations[77]. Environmental, Social, and Governance (ESG) Initiatives - The company emphasizes sustainable development as key to long-term success and has integrated environmental, social, and governance (ESG) principles into its business strategy[134]. - A working group has been established to enhance employee awareness of ESG issues and to collect and analyze relevant data[139]. - The company aims to create sustainable value for shareholders while pursuing a responsible and sustainable business model[138]. - The environmental, social, and governance (ESG) report focuses on the group's operations as a medical device distributor in Hong Kong, which is the main source of revenue[145]. - Key ESG issues identified include greenhouse gas emissions, waste management, resource usage, and climate change, among others[151]. - The group is committed to continuous evaluation of its ESG risk management and internal control systems to improve performance and data collection[151]. - The company has adopted a corporate social responsibility policy focused on waste management principles, including reduction, reuse, recycling, and alternative use[156]. - The company aims to reduce greenhouse gas emissions and has set a target to maintain or lower emissions density by the fiscal year ending March 31, 2030[157]. Employee Development and Training - The company has hired additional personnel, including seven product representatives and two engineers, to expand its workforce[34]. - Employee development programs have been enhanced, with a focus on training that has improved staff retention rates by 15%[56]. - Approximately 39% of employees received training during the reporting period, down from 100% in FY2022[195]. - Average training hours per employee decreased to 9.0 hours in FY2023 from 9.9 hours in FY2022[195]. - Senior management training hours increased significantly from 2.0 hours in FY2022 to 3.4 hours in FY2023, an increase of 70%[199]. - The company maintained a zero-tolerance policy towards any form of workplace harassment or abuse[189]. Risk Management - The company has established a risk management policy to identify, assess, and manage key risks affecting the business, with regular quarterly reviews[109]. - The board confirmed that there are no significant deficiencies in the company's risk management and internal control systems[110]. - The company has adopted a whistleblowing policy to promote a culture of compliance and ethical behavior, with no significant fraud or misconduct reported for the fiscal year ending March 31, 2023[111]. - The company has implemented an anti-corruption policy as part of its corporate governance framework, ensuring adherence to applicable anti-corruption laws and regulations[113].

香港交易及結算所有限公司及香港聯交所對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 GRAND BRILLIANCE GROUP HOLDINGS LIMITED 君 百 延 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8372） 截 至2023年3月31日 止 年 度 之 全 年 業 績 公 告 香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的 定 位 乃 為 相 比 起 其 他 在 香 港 聯 交 所 上 市 的 公 司 帶 有 較 高 投 資 風 險的中小型公司提供一個上市的市場。有意投資人士應瞭解投資該等公 司 的 潛 在 風 險，並 應 經 過 審 慎 周 詳 考 慮 後 方 作 出 投 資 決 定。GEM的 較 高 風險及其他特色表示GEM較適合專業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港 聯交所主板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦 不保證會有高流通量的市場。 本公告（ ...

本公司董事會（「董事會」）欣然公佈本集團截至2022年12月31日止九個月的未經審 核簡明綜合業績（連同2021年同期的比較數字）如下： 香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的定位乃為相比起其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應了解投資該等公司的潛在風險，並應經過 審慎周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（君百延集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」或「我 們」）各董事（「董事」）願就此共同及個別承擔全部責任）乃遵照香港聯交所GEM證券 上市規則（「GEM上市規則」）提供有關本集團的資料。各董事經作出 ...

(Incorporated in the Cayman Islands with limited liability) Stock code: 8372 2022 INTERIM REPORT （於開曼群島註冊成立的有限公司） 股份代號：8372 2022 中期報告 香港聯合交易所有限公司(「香港聯交所」) GEM 的特色 GEM 的定位乃為相比超其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應了解投資該等公司的潛在風險,並應經過 審償周詳考慮後方作出投資決定。GEM 的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然,在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告(君百延集團控股有限公司(「本公司」,連同其附屬公司統稱「本集團」或「我 們」} ...

Financial Performance - The Group reported revenue of HKD 15,696,000 for the three months ended June 30, 2022, representing an increase of 12.1% compared to HKD 14,006,000 in the same period of 2021[8]. - Gross profit for the same period was HKD 7,878,000, up from HKD 7,275,000, indicating a growth of 8.3% year-on-year[8]. - The Group's net profit attributable to owners for the period was HKD 1,079,000, compared to HKD 727,000 in the previous year, reflecting a significant increase of 48.3%[8]. - Basic and diluted earnings per share increased to HKD 0.13 from HKD 0.09, marking a growth of 44.4%[8]. - The total comprehensive income for the period was HKD 1,079,000, compared to HKD 727,000 in the same period last year, showing an increase of 48.3%[8]. - The Group's cost of revenue was HKD 7,818,000, which is an increase from HKD 6,731,000, resulting in a higher cost structure[8]. - Administrative and other operating expenses rose to HKD 6,495,000 from HKD 6,179,000, indicating a year-on-year increase of 5.1%[8]. - The Group's financial costs, including losses from associates, were HKD 34,000, consistent with the previous year[8]. - The Group's other income increased significantly to HKD 280,000 from HKD 12,000, reflecting a growth of 2,233.3%[8]. Revenue Sources - The company's revenue increased approximately 12% from about HKD 14,000,000 for the three months ended June 30, 2021, to about HKD 15,700,000 for the three months ended June 30, 2022, primarily due to increased revenue from medical consumables[53]. - Revenue from medical consumables was HKD 11,970,000 for the three months ended June 30, 2022, compared to HKD 10,351,000 for the same period in 2021, representing an increase of approximately 15.6%[33]. - The company reported a total revenue of HKD 15,696,000 from various sources for the three months ended June 30, 2022, compared to HKD 14,006,000 for the same period in 2021[33]. Research and Development - Research and development expenses amounted to approximately HKD 614,000 for the three months ended June 30, 2022, compared to HKD 141,000 for the same period in 2021, reflecting a significant increase in investment in R&D[38]. - The company has established a joint venture to promote and develop autonomous mobile robotic solutions in the healthcare sector, aiming to support business growth and expand its operations[50]. - The company plans to further diversify its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[50]. Tax and Dividends - The company incurred a tax expense of HKD 220,000 for the three months ended June 30, 2022, compared to HKD 150,000 for the same period in 2021, representing an increase of approximately 46.7%[42]. - The company did not declare any dividends for the three months ended June 30, 2022, consistent with the previous year[43]. - The board resolved not to declare any dividend for the three months ended June 30, 2022[59]. Market Outlook - The company continues to maintain a positive outlook on the healthcare industry, driven by an aging population and increasing health awareness among Hong Kong citizens[50]. Employee and Governance - The group’s employee costs increased due to the expansion of the workforce during the three months ended June 30, 2022[55]. - The company adopted a share option scheme on March 1, 2018, to incentivize selected participants for their contributions to the group[70]. - As of June 30, 2022, no share options were granted, exercised, forfeited, cancelled, or lapsed during the period[73]. - All directors confirmed compliance with the trading standards and relevant codes of conduct during the three months ended June 30, 2022[77]. - There were no conflicts of interest reported among directors or their associates in businesses that compete or may compete with the group as of June 30, 2022[79]. - The company has adopted the new corporate governance code effective January 1, 2022, and has complied with all provisions except for specific deviations[82]. - The roles of the chairman and CEO are held by the same individual, which the board believes does not compromise its independence or effectiveness[83]. - The audit committee, consisting of two independent non-executive directors and one non-executive director, reviewed the unaudited consolidated financial statements for the three months ended June 30, 2022[85].

Financial Performance - The group's revenue increased by approximately 2.5% from about HKD 70.2 million for the year ended March 31, 2021, to about HKD 72 million for the year ended March 31, 2022, primarily due to increased sales of medical gloves and biopsy needles [12]. - Gross profit rose by approximately HKD 2.7 million or 8.1% from about HKD 33.6 million for the year ended March 31, 2021, to about HKD 36.3 million for the year ended March 31, 2022, with the gross profit margin increasing from approximately 47.9% to about 50.5% [13]. - The group's profit decreased from approximately HKD 7,900,000 for the year ended March 31, 2021, to approximately HKD 4,000,000 for the year ended March 31, 2022, mainly due to increased employee costs and a one-time government subsidy in the previous year [18]. - The income tax expense for the year ended March 31, 2022, was approximately HKD 1.4 million, compared to about HKD 1.5 million in 2021 [15]. - The board declared an interim dividend of HKD 0.3 per share for the year ended March 31, 2022, down from HKD 0.45 per share in 2021 [19]. Operational Challenges and Strategies - The group continues to face challenges due to the significant impact of COVID-19 on the economy and customer spending plans [11]. - The group remains optimistic about the healthcare sector due to the growing elderly population and increasing medical awareness among Hong Kong citizens [8]. - The group is actively seeking suitable investment opportunities to diversify its business and enhance returns for shareholders [8]. - The group is focused on leveraging its strengths to diversify its product offerings and expand its customer base [8]. - The group plans to further expand its product portfolio and strengthen customer service to enhance its one-stop medical instrument solution services [11]. Human Resources and Employee Costs - Administrative and other operating expenses increased by approximately HKD 3.8 million or 15.2% from about HKD 25.4 million for the year ended March 31, 2021, to about HKD 29.2 million for the year ended March 31, 2022, mainly due to an increase in the number of employees [14]. - The group employed a total of 41 staff as of March 31, 2022, with employee costs amounting to approximately HKD 18,200,000, an increase from approximately HKD 15,600,000 in 2021 [34]. - The group is actively seeking strategic acquisition opportunities and has hired additional personnel to enhance product development capabilities [39]. Assets and Liabilities - As of March 31, 2022, current assets were approximately HKD 97,400,000, a decrease from approximately HKD 101,800,000 in 2021, while current liabilities decreased to approximately HKD 14,700,000 from HKD 17,500,000 [20]. - The group's cash and bank balances totaled approximately HKD 55,300,000 as of March 31, 2022, down from approximately HKD 70,200,000 in 2021 [21]. - Trade receivables increased to approximately HKD 17,300,000 as of March 31, 2022, compared to approximately HKD 7,700,000 in 2021 [22]. - The group had no significant debt financing, resulting in a debt-to-asset ratio of zero as of March 31, 2022 [23]. Corporate Governance - The company has adopted a new corporate governance code to enhance transparency and accountability, effective from January 1, 2022 [68]. - All directors confirmed compliance with trading standards and ethical guidelines, ensuring no violations occurred during the reporting period [70]. - The board consists of six directors responsible for overall business development goals and long-term company strategy [72]. - The company held four regular meetings and one annual general meeting during the fiscal year ending March 31, 2022 [75]. - The board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, to enhance governance [85]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to sustainable development, integrating environmental, social, and governance (ESG) principles into its business strategy to ensure long-term prosperity [146]. - The board of directors evaluates the potential impact of ESG issues on the overall strategy and monitors the company's performance in these areas [148]. - The company has established goals related to significant ESG issues and actively implements measures to enhance its performance in these areas [149]. - The group has established a working group to enhance employee awareness of environmental, social, and governance (ESG) issues, comprising senior management and staff from various departments [151]. - The ESG report focuses on the operations as a medical device distributor, which is the primary source of revenue for the group, and has expanded its reporting scope due to business growth [152]. Emissions and Resource Management - Direct greenhouse gas emissions (Scope 1) were 21 tons of CO2 equivalent, a decrease from 23 tons in the previous fiscal year [178]. - Total greenhouse gas emissions increased to approximately 53 tons of CO2 equivalent, up about 18% from 45 tons in the previous fiscal year [178]. - The total amount of non-hazardous waste generated was approximately 854 kilograms, an increase of about 15% from 740 kilograms in the previous fiscal year [183]. - The company has set a target to maintain or reduce non-hazardous waste density to approximately 11.86 kilograms per million revenue by the fiscal year 2030 [183]. - The company has implemented various energy and resource-saving measures to achieve its emission reduction goals [172].

Financial Performance - For the three months ended December 31, 2021, the company reported revenue of HKD 20,344,000, an increase of 35% compared to HKD 15,100,000 for the same period in 2020[8] - The gross profit for the three months ended December 31, 2021, was HKD 10,036,000, representing a gross margin of 49.3%, up from HKD 8,159,000 in the same period last year[8] - The net profit attributable to the owners of the company for the three months ended December 31, 2021, was HKD 2,108,000, an increase of 3.6% from HKD 2,035,000 in the previous year[8] - For the nine months ended December 31, 2021, total revenue reached HKD 51,699,000, a 24% increase from HKD 41,244,000 in the same period of 2020[8] - The company’s total comprehensive income for the nine months ended December 31, 2021, was HKD 5,159,000, compared to HKD 4,905,000 for the same period in 2020[8] - The group reported a revenue of HKD 51,699,000 for the nine months ended December 31, 2021, compared to HKD 45,745,000 for the same period in 2020, representing an increase of approximately 12.7%[29] - Revenue from medical consumables was HKD 36,653,000 for the nine months ended December 31, 2021, slightly up from HKD 36,365,000 in the same period of 2020[29] - Revenue from medical equipment surged to HKD 11,832,000 for the nine months ended December 31, 2021, compared to HKD 6,046,000 in the same period of 2020, marking a significant increase of approximately 95.5%[29] - The group’s pre-tax profit for the nine months ended December 31, 2021, was impacted by an increase in employee costs, which rose to HKD 12,052,000 from HKD 10,198,000 in the same period of 2020[36] - The company's profit attributable to shareholders for the nine months ended December 31, 2021, decreased to approximately HKD 5,200,000 from HKD 7,700,000 for the same period in 2020, a reduction of about 32.5%[58] - Revenue increased by approximately 13.0% to about HKD 51,700,000 for the nine months ended December 31, 2021, compared to approximately HKD 45,700,000 for the same period in 2020, primarily due to increased sales of medical equipment[51] - Gross profit for the nine months ended December 31, 2021, was approximately HKD 27,200,000, an increase of about HKD 2,000,000 or 8.2% from HKD 25,200,000 for the same period in 2020[52] - The gross profit margin decreased from approximately 55.0% for the nine months ended December 31, 2020, to about 52.7% for the same period in 2021, mainly due to an increase in sales of lower-margin medical equipment[52] Expenses and Costs - Administrative and other operating expenses for the three months ended December 31, 2021, were HKD 6,751,000, an increase from HKD 5,461,000 in the same period last year[8] - Administrative and other operating expenses increased by approximately 15.0% to about HKD 19,600,000 for the nine months ended December 31, 2021, from approximately HKD 17,000,000 for the same period in 2020, primarily due to an increase in the workforce[53] - The group’s finance costs for the nine months ended December 31, 2021, included interest on lease liabilities of HKD 106,000, up from HKD 70,000 in the same period of 2020[31] - Income tax expense for the nine months ended December 31, 2021, was approximately HKD 1,300,000, compared to HKD 1,600,000 for the same period in 2020[54] Dividends and Shareholder Returns - The group did not declare an interim dividend for the nine months ended December 31, 2021, compared to HKD 3,500,000 declared for the same period in 2020[40] - The company decided not to declare an interim dividend for the nine months ended December 31, 2021, consistent with the previous year[59] Market and Business Strategy - The company continues to focus on its core business of supplying medical instruments and providing related solutions[14] - The company remains optimistic about the healthcare sector's prospects due to increasing demand for resources and solutions, an aging population, and rising healthcare awareness among the public[48] - The company plans to further diversify its product offerings and enhance customer service to improve its one-stop medical equipment solution services[48] - The company is actively seeking suitable investment opportunities to diversify its business and provide better returns to shareholders[48] - The group plans to continue focusing on expanding its market presence in Hong Kong, where all revenues are currently generated, and has no separate segment analysis due to its operational structure[24] Governance and Compliance - The financial statements have been prepared in accordance with the Hong Kong Financial Reporting Standards and have not been audited[20] - The audit committee has reviewed the unaudited consolidated financial statements for the nine months ending December 31, 2021, confirming compliance with applicable accounting standards and GEM listing rules[86] - The company has maintained compliance with all corporate governance code provisions, except for the separation of the roles of chairman and CEO[81] - The company’s board of directors has confirmed adherence to trading standards and relevant codes of conduct as of December 31, 2021[78] - The company has established independent checks to ensure the effectiveness and independence of the board despite the CEO also serving as chairman[84] - The company has a diverse board with members possessing various professional backgrounds and expertise, ensuring robust governance[84] Share Options and Securities - The company has adopted a share option scheme to incentivize selected participants, with a total of 21,460,000 options available for exercise as of December 31, 2021[74] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ending December 31, 2021[77] - The company has not granted, exercised, or forfeited any share options during the nine months ending December 31, 2021[74] - As of December 31, 2021, B&A Success holds 557,424,000 shares, representing a 69.68% equity stake in the company[69] Research and Development - Research and development expenses amounted to approximately HKD 1,150,000 for the nine months ended December 31, 2021, compared to HKD 363,000 for the same period in 2020, indicating a substantial increase in investment in R&D[36] Customer Contributions - The group had a significant customer contributing HKD 6,498,000, accounting for over 10% of total revenue for the nine months ended December 31, 2021, compared to HKD 5,459,000 from a similar customer in the same period of 2020[26] No New Developments - The company has not announced any new products or technologies during this reporting period[8] - There are no significant market expansions or acquisitions reported in the current financial results[8]

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於同曼群島註冊成立的有限公司) 股份代號：8372 香港聯合交易所有限公司(「香港聯交所」) GEM 的特色 GEM 的定位乃為相比超其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險,並應經過 審償周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然,在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責,對其準確性或 完整性亦不發表任何聲明,並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告(君百延集團控股有限公司(「本公司」,連同其附屬公司統稱「本集團」或「我 們」} 各 董事(「董事」) 願就此共同及個別承擔全部責任）乃遵照香港聯交所 GEM 證券 上市規則(「GEM上市規則」 ...

Grand Brilliance Group Holdings Limited 君百延集團控股有限公司 (於同曼群島註冊成立的有限公司) 股份代號：8372 第 香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的定位乃為相比起其他在香港聯交所上市的公司帶有較高投資風險的中小型公 司提供一個上市的市場。有意投資人士應瞭解投資該等公司的潛在風險，並應經過 審慎周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專 業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港聯交所主 板買賣的證券容易受到市場波動的影響。在GEM買賣的證券亦不保證會有高流通量 的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（君百延集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」或「我 們」）各董事（「董事」）願就此共同及個別承擔全部責任）乃遵照香港聯交所GEM證券 上市規則（「GEM上市規則」）提供有關本 ...

Financial Performance - The group's revenue increased by approximately 4.5% from about HKD 67.2 million for the year ended March 31, 2020, to about HKD 70.2 million for the year ended March 31, 2021, primarily due to strong sales of the pharmacy automation system[13]. - Gross profit decreased by approximately HKD 2.8 million or 7.6% from about HKD 36.4 million for the year ended March 31, 2020, to about HKD 33.6 million for the year ended March 31, 2021, with the gross profit margin dropping from approximately 54.1% to 47.9%[14]. - Net profit decreased by approximately HKD 1.7 million from about HKD 9.6 million for the year ended March 31, 2020, to about HKD 7.9 million for the year ended March 31, 2021, mainly due to the reduction in gross profit[18]. - Administrative and other operating expenses increased by approximately HKD 1 million or 4.0% from about HKD 24.4 million for the year ended March 31, 2020, to about HKD 25.4 million for the year ended March 31, 2021, primarily due to an increase in the number of employees[15]. - The income tax expense for the year ended March 31, 2021, was approximately HKD 1.5 million, down from HKD 2.3 million in 2020[16]. - The total cash and bank balances as of March 31, 2021, were approximately HKD 70.2 million, slightly down from HKD 70.6 million in 2020[21]. - The group had no significant capital commitments or major investments as of March 31, 2021, maintaining a debt-free status with a debt-to-asset ratio of zero[22][29]. - Employee costs for the year ended March 31, 2021, were approximately HKD 15.6 million, up from HKD 14 million in 2020, with a total of 34 employees compared to 33 in the previous year[33]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.45 per ordinary share for the year ended March 31, 2021, compared to HKD 0.4375 per share for 2020[19]. - The dividend policy considers factors such as actual and expected financial performance, capital and debt levels, and operational funding needs[132]. - Dividends may be paid in cash or through the issuance of shares, subject to legal and regulatory compliance[134]. - The board has the discretion to decide on dividend payments based on various factors, including capital structure and future opportunities[137]. - The dividend policy is published on the company's website for investor reference[139]. Market and Product Development - The company successfully supplied Hong Kong's first pharmacy automation system, enhancing its position as a pioneer in this technology[9]. - The company remains optimistic about the healthcare sector's prospects due to the growing elderly population and increasing healthcare awareness among Hong Kong citizens[9]. - The company plans to further diversify its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[12]. - The company aims to address the healthcare workforce shortage in Hong Kong through its automation solutions[9]. - The actual net proceeds from the share offering were approximately HKD 31.2 million, with a difference of HKD 1.9 million from the estimated proceeds of HKD 33.1 million disclosed in the prospectus[37]. - The group plans to utilize HKD 6.1 million for further penetration into the medical device market, with HKD 5.5 million remaining to be used by March 31, 2022[39]. - The company is focused on expanding its market presence and developing new products and technologies to enhance its competitive edge[44][52]. - New product launches are expected to contribute an additional HKD 200 million in revenue, with a focus on enhancing user experience and engagement[75]. - Market expansion efforts include entering two new regions, which are anticipated to increase market share by 5%[75]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a budget of up to HKD 300 million allocated for potential deals[75]. Corporate Governance and Management - The company is committed to maintaining high standards of corporate governance and compliance through its various committees[44][50]. - The board consists of six members, including the Chairperson and CEO, ensuring a balanced composition in terms of age, gender, and tenure[64]. - The company held four regular meetings and one annual general meeting during the fiscal year ending March 31, 2021[65]. - The attendance record for board meetings shows that all directors participated actively, with most attending 100% of the meetings[68]. - The company has a strong focus on risk management and internal controls, delegating daily operations and business development plans to the management team[71]. - The management team is required to obtain board approval before entering into any significant transactions or contracts[71]. - The company has maintained a high level of corporate governance, which is crucial for enhancing corporate value and accountability[60]. - The board includes independent non-executive directors, with at least one possessing appropriate professional qualifications in accounting or related financial management[71]. - The company emphasizes transparency and shareholder rights as part of its governance practices[60]. - The management team has over 20 years of experience in accounting, auditing, and financial management, contributing to the company's strategic direction[58]. - The company has established a robust investor relations strategy to communicate effectively with stakeholders[48]. - The company has established measurable goals for board member diversity and monitors progress towards achieving these goals[102]. Environmental, Social, and Governance (ESG) Initiatives - The report emphasizes the importance of integrating environmental, social, and governance (ESG) principles into the company's risk management system[141]. - The ESG report covers activities, challenges, and measures taken during the fiscal year ending March 31, 2021[146]. - Stakeholder engagement is prioritized, with communication channels established for feedback from shareholders, customers, suppliers, and regulatory bodies[148]. - Key performance indicators related to ESG are collected and reported, focusing on direct operational control within the company and its subsidiaries[143]. - The company is committed to continuous assessment and improvement of its ESG risk management and internal control systems[155]. - The report identifies significant ESG issues, including product safety, employee welfare, and regulatory compliance[155]. - The company has established a whistleblowing mechanism for stakeholders to report suspected misconduct or policy violations[158]. - The ESG report is prepared in accordance with the guidelines set forth by the Hong Kong Stock Exchange[144]. - The company aims to create greater value for the community through collaboration with stakeholders and addressing their expectations[148]. - The total greenhouse gas emissions decreased from approximately 55 tons of CO2 equivalent in FY2020 to about 45 tons in FY2021, representing a reduction of approximately 18.2%[167]. - The total paper consumption decreased from approximately 836 kg in FY2020 to about 740 kg in FY2021, a reduction of approximately 11.5%[175]. - The company has implemented various energy-saving measures to achieve its emission reduction and energy efficiency goals[162]. - The company has not reported any significant violations of environmental laws and regulations during the reporting period[167]. - Energy consumption decreased from approximately 146,139 kWh in FY2020 to about 132,563 kWh in FY2021, representing a reduction of approximately 9.3%[181]. - Total water consumption reduced from approximately 8 cubic meters in FY2020 to 3 cubic meters in FY2021, a decrease of about 62.5%[184]. - The company encourages employees to participate in activities promoting a green environment, enhancing awareness of energy management[181]. - The company has established policies to ensure fair treatment and equal opportunities for all employees, with a zero-tolerance approach to workplace harassment[199].